Trident Pharmaceuticals Announces Initiation Of Phase 1a – Pharmaceutical Online (press release)

Trident Pharmaceuticals Announces Initiation Of Phase 1a
Pharmaceutical Online (press release)
HF1020 is believed to offer a novel approach for treating the underlying inflammatory pathology of autoimmune disease and allergic asthma, without causing systemic immunosupression. HF1020 is an oral biopharmaceutical product which acts by inducing

and more »

View full post on asthma – Google News

Trident Pharmaceuticals Announces Initiation of Phase 1a Clinical Study of HF1020 – MarketWatch (press release)

Trident Pharmaceuticals Announces Initiation of Phase 1a Clinical Study of HF1020
MarketWatch (press release)
HF1020 is believed to offer a novel approach for treating the underlying inflammatory pathology of autoimmune disease and allergic asthma, without causing systemic immunosupression. HF1020 is an oral biopharmaceutical product which acts by inducing

and more »

View full post on asthma – Google News